Beneficial effects of pravastatin on fasting hyperinsulinemia in elderly hypertensive hypercholesterolemic subjects
Beneficial effects of pravastatin on fasting hyperinsulinemia in elderly hypertensive hypercholesterolemic subjects
复制标题
DOI：
10.1161/01.hyp.28.4.647
复制
发表时间：
1996-10-01
期刊：
影响因子：
8.3
通讯作者：
Lee, YS
中科院分区：
文献类型：
--
作者：
Chan, P;Tomlinson, B;Lee, YS
我们进行了这项前瞻性双盲、安慰剂对照研究，以评估低剂量（15mg）普伐他汀在同时接受降压治疗的老年高胆固醇血症性高血压患者中的疗效和安全性，并确定是否也可以改善空腹高胰岛素血症。在两个医疗中心的三个高血压和血脂门诊，96名老年人（49名女性，47名男性）在3个月的单盲先导期后被随机分为积极治疗组或安慰剂组，为期12个月。血浆总胆固醇水平至少为6.47 mmol/L (250 mg/dL)，甘油三酯水平低于3.39 mmol/L （300 mg/dL）的高血压患者在接受3个月的美国心脏协会第一步饮食后，使用15 mg普伐他汀治疗12个月。测量脂质、葡萄糖和空腹胰岛素水平；临床实验室检查包括肝功能和肌酸激酶测定。普伐他汀治疗12个月后，血浆总胆固醇浓度下降25.1%(从平均7.29降至5.47 mmol/L， P
We undertook this prospective double-blind, placebo-controlled study to evaluate the efficacy and safety of low-dose (15 mg) pravastatin in elderly hypercholesterolemic hypertensive subjects with concurrent antihypertensive treatment and to determine whether fasting hyperinsulinemia could also be improved. At three hypertension and lipid clinics of two medical centers, 96 elderly (49 women, 47 men) ambulatory subjects were randomized to active treatment or placebo for 12 months after a 3-month single-blind lead-in period. Hypertensive subjects with plasma total cholesterol levels of at least 6.47 mmol/L (250 mg/dL) and triglyceride levels less than 3.39 mmol/L (300 mg/dL) were treated with 15 mg pravastatin for 12 months after receiving 3 months of the American Heart Association step I diet. Lipid, glucose, and fasting insulin levels were measured; clinical laboratory tests included liver function and creatine kinase determinations. After 12 months of pravastatin therapy, plasma total cholesterol concentration decreased by 25.1% (from a mean of 7.29 to 5.47 mmol/L, P